AbolerIS Pharma: Funding, Investors & Team (Sep 2026)
AbolerIS Pharma offers a unique and innovative method to promote immune tolerance and maintain beneficial immune responses in conditions like inflammation, autoimmunity, and degeneration. This enables scientists to focus on creating new medications in critical areas where medical requirements remain unfulfilled.
AbolerIS Pharma has raised $29.2M across 1 funding round on record, the most recent a Series A of $29.2M announced in Sep 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
AbolerIS Pharma Company Profile and Key Stats
Latest funding round on record: Sep 2023.
AbolerIS Pharma Funding Rounds
AbolerIS Pharma Founders and Leadership Team
No contact details are on record for this team yet.
AbolerIS Pharma Funding Compared to Other Biotechnology Startups
AbolerIS Pharma's latest round of $29.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like AbolerIS Pharma in Biotechnology and Nantes
Companies Similar to AbolerIS Pharma
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
AbolerIS Pharma Funding FAQs
What does AbolerIS Pharma do?
AbolerIS Pharma offers a unique and innovative method to promote immune tolerance and maintain beneficial immune responses in conditions like inflammation, autoimmunity, and degeneration. This enables scientists to focus on creating new medications in critical areas where medical requirements remain unfulfilled.
How much funding has AbolerIS Pharma raised?
AbolerIS Pharma has raised $29.2M across 1 round on record. The most recent is a Series A of $29.2M announced in Sep 2023.
When did AbolerIS Pharma last raise funding?
AbolerIS Pharma's most recent funding round on record is a Series A of $29.2M, announced in Sep 2023.
Who founded AbolerIS Pharma?
FundedIQ lists Carole Guillonneau (Founder) at AbolerIS Pharma.
Where is AbolerIS Pharma headquartered?
AbolerIS Pharma is based in Nantes, Pays De La Loire, France.
How many employees does AbolerIS Pharma have?
AbolerIS Pharma is in the 11-50 employee band.
How does AbolerIS Pharma's funding compare to other Biotechnology startups?
AbolerIS Pharma's latest round of $29.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's AbolerIS Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for AbolerIS Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.